Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is great news ...RDHL incredibly undervalued at this stage
Teva Announces Voluntary Suspension of Marketing for ZECUITY® in the U.S.
http://finance.yahoo.com/news/teva-announces-voluntary-suspension-marketing-120000155.html
Good news for PTX?
www.bionapcfa.com/2016/03/redhill-biopharma-packed-with-catalysts.html
http://zolmax.com/investing/zacks-can-fite-biopharma-ltd-nasdaqcanf-given-average-recommendation-of-strong-buy-by-analysts/303760/
Zacks: Can Fite Biopharma Ltd (NASDAQ:CANF) Given Average Recommendation of “Strong Buy” by Analysts
Posted by Bonnie Powley on Jan 12th, 2016 // No Comments
Can Fite Biopharma Ltd (NASDAQ:CANF) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $6.75 for the company and are forecasting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Can Fite Biopharma an industry rank of 53 out of 265 based on the ratings given to related companies.
Can Fite Biopharma (NASDAQ:CANF) traded down 3.33% during midday trading on Tuesday, reaching $2.32. The company’s stock had a trading volume of 97,383 shares. The company’s market cap is $24.98 million. Can Fite Biopharma has a 12 month low of $1.46 and a 12 month high of $64.71. The stock has a 50-day moving average price of $4.92 and a 200 day moving average price of $3.23.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Can Fite Biopharma in a report on Thursday, January 7th.
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Evoke Pharma Strengthens Financial Position
finance.yahoo.com/news/evoke-pharma-strengthens-financial-position-123000384.html
Might break 5...
More analysts' coverage now: Price Target 13-27. http://www.google.com/finance?q=NASDAQ%3AEVOK&ei=oDcNVrClGMuKUoemk4gG
I think we may break 4 today
nice!!!
KEYTRADE
BELGIUM got CGRP's dividend today too!!!!!
Unbelievable, I am so happy!!!
CRGP is the real deal!!!
Thanks Gilbert i bought on 17 august but real value date for purchase US stocks with keytrade is d+2 so 19 august .. I think i Will not get anything??
Could you send me their answer by email at fvdbril@yhoo.com. Thanks
Hello Gilbert was it a positive answer from keytrade i am with them as well thanks and bought on 16 august.
Now that the company has kept its promise for the divvy and based on your great valuation, the SP is deemed to EXPLODE...
Amazing congrats...
thanks because my broker does not seem to be willing to answer that one. I got as an answer 30 June record date only...
simple dividend question:
among the investors that already received their cash dividends, can someone confirm that it was linked to his/her shares bought AFTER 30 June?
thanks!
I have thanks a lot...but no answer yet. Will keep informed..
Wait and see here
Were you an owner on 30 June thanks
I agree for me it is essential to know if we are entitled to the divvy if we were not owners on 30 June
Hello i am from Belgium as well. My broker confirmed the divvy but for those that had the stock on 30 June. Do not know if i will get it as i bought one week ago...
it was done this morning
THIS SHOULD BE STICKIED THANKS
INVESTOPEDIA EXPLAINS 'Ex-Dividend'
A stock trades ex-dividend on or after the ex-dividend date (ex-date). At this point, the person who owns the security on the ex-dividend date (ie 08/19) will be awarded the payment, regardless of who currently holds the stock. After the ex-date has been declared, the stock will usually drop in price by the amount of the expected dividend.
THIS SHOULD BE STICKIED FINRA DIVVY EVIDENCE
Answer of 26 May from Cdii.net concerning the annual report:
Hi XXX,
We are currently still working out some issues with Big Tree, so unfortunately we don’t know for sure when they will be able to complete the annual reports. I will forward your concern to the management at Big Tree and hopefully get a better answer to your questions for you. Thank you for your patience.
Peisha Shen
Of course, this is always the same old answer but it means the annual will be out one day...Patience again...
Sharky,
I sent an email to Peisha on May, 5 and got no answer this time. Expecting news soon to make up for this silence
From Bigg's website (http://www.bigtreegroup.net/index.php/news/81-12-02-2013-big-tree-group-provides-financial-forecast-for-2013-year-end-financial-results-and-outlook-for-2014):
Big Tree Group estimates it will achieve record revenue exceeding $45 million with earnings per share of approximately $0.14 for the full fiscal year of 2013 ending December 31, 2013. Management further believes the successful implementation of the Company’s more aggressive pricing strategy to increase international market share throughout the course of 2013, coupled with a strengthening global economy, have set the stage for Big Tree to achieve substantial financial growth in fiscal 2014. Big Tree Group sees full year revenue in fiscal 2014 reaching $60 million with earnings per share exceeding $0.20.
In 2013, they actually reported $39,727,002, not far from their estimate. Could it be the same pattern for 2014 and a rough 50,000,000?
We can always dream on...But it that would come true, shares would explode at .15 in a jiffy...
Nobody knows really...but the form filed end of March means surely something :good or bad omen...let us see what May bring...no need to sell at this point imho
This wall si peanuts if News hit ...
Agreed. All we need for that is News
L2 anyone? Thanks